Therapeutic anti-cancer targets upstream of the proteasome

Cancer Treatment Reviews

Volumn 29, Issue SUPPL. 1, 2003, Pages 49-57

  Nalepa, Grzegorz ^a   Harper, J Wade ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Cullin; F box protein; Nedd8; Oncogene; Proteasome; Proteolysis; Therapeutic; Ubiquitin ligase

Indexed keywords

ANTINEOPLASTIC AGENT; BORTEZOMIB; CELL PROTEIN; PROTEASOME; PROTEASOME INHIBITOR; PROTEIN MDM2; PROTEIN P53; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; UBIQUITIN; UBIQUITIN CONJUGATING ENZYME; UBIQUITIN PROTEIN LIGASE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER RESEARCH; CELL CYCLE; CELL PROLIFERATION; DNA FLANKING REGION; DNA STRUCTURE; DRUG EFFICACY; DRUG TARGETING; HUMAN; NONHUMAN; PROTEIN DEGRADATION; PROTEIN FAMILY; PROTEIN MODIFICATION; PROTEIN TARGETING; REVIEW;

EID: 0038189900     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0305-7372(03)00083-5     Document Type: Review

References (55)

1. Hershko A, Ciechanover A. The ubiquitin system. Annu Rev Biochem 1998; 67: 425-479.
2. Koepp DM, Harper JW, Elledge SJ. How the cyclin became a cyclin: regulated proteolysis in the cell cycle. Cell 1999; 97(4): 431-434.
3. Hicke L. Protein regulation by monoubiquitin. Nat Rev Mol Cell Biol 2001; 2(3): 195-201.
4. Richardson PG, Barlogie B, Berenson J, et al. Phase II study of the proteasome inhibitor PS-341 in multiple myeloma patients (Pts) with relapsed/refractory disease: results from Cohort1 analysis. Proceedings of the American Society of Clinical Oncology - 38th Annual Meeting 2002; 21: 11a.
5. Orlowski RZ, Hall M, Voorhees P, et al, Phase I study of the proteasome inhibitor bortezomib (PS-341, Velcade) in combination with pegylated liposomal doxorubicin (doxil) in patients with refractory hematologic malignancies. Blood 2002; 100(11): 105a.
6. Aghajanian C, Soignet S, Dizon DS, et al. A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin Cancer Res 2002; 8(8): 2505-2511.
7. Adams J. Development of the proteasome inhibitor PS-341. Oncologist 2002; 70(1): 9-16.
8. Gille H, Downward J. Multiple ras effector pathways contribute to G(1) cell cycle progression. J Biol Chem 1999; 274(31): 22033-22040.
9. Sears R, Leone G, DeGregori J, Nevins JR. Ras enhances myc protein stability. Mol Cell 1999; 3(2): 169-179.
10. Sears R, Nuckolls F, Haura E, Taya Y, Tamai K, Nevins JR. Multiple ras-dependent phosphorylation pathways regulate myc protein stability. Genes Dev 2000; 14(19): 2501-2514.
11. He TC, Sparks AB, Rago C, et al. Identification of C-MYC as a target of the APC pathway. Science 1998; 281(5382): 1509-1512.
12. Wang TC, Cardiff RD, Zukerberg L, Lees E, Arnold A, Schmidt EV. Mammary hyperplasia and carcinoma in MMTV-Cyclin D1 transgenic mice. Nature 1994; 369(6482): 669-671.
13. Bortner DM, Rosenberg MP. Induction of mammary gland hyperplasia and carcinomas in transgenic mice expressing human cyclin E. Mol Cell Biol 1997; 17(1): 453-459.
14. Sherr CJ. Cancer cell cycles. Science 1996; 274(5293): 1672-1677.
15. Keyomarsi K, Tucker SL, Buchholz TA, et al. Cyclin E and survival in patients with breast cancer. N Engl J Med 2002; 347(20): 1566-1575.
16. Harper JW, Elledge SJ. Cdk inhibitors in development and cancer. Curr Opin Genet Dev 1996; 6(1): 56-64.
17. Porter PL, Malone KE, Heagerty PJ, et al. Expression of cell-cycle regulators P27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nat Med 1997; 3(2): 222-225.
18. Loda M, Cukor B, Tam SW, et al. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor P27 in aggressive colorectal carcinomas. Nat Med 1997; 3(2): 231-234.
19. Catzavelos C, Bhattacharya N, Ung YC, et al. Decreased levels of the cell-cycle inhibitor P27Kip1 protein: prognostic implications in primary breast cancer. Nat Med 1997; 3(2): 227-230.
20. Chiarle R, Pagano M, Inghirami G. The cyclin dependent kinase inhibitor P27 and its prognostic role in breast cancer. Breast Cancer Res 2001; 3(2): 91-94.
21. Di Cristofano A, De Acetis M, Koff A, Cordon-Cardo C, Pandolfi PP. PTEN and P27KIP1 cooperate in prostate cancer tumor suppression in the mouse. Nat Genet 2001; 27(2): 222-224.
22. Zheng N, Schulman BA, Song L, et al. Structure of the Cul1-Rbx1-Skp1-F BoxSkp2 SCF ubiquitin ligase complex. Nature 2002; 416(6882): 703-709.
23. Strohmaier H, Spruck CH, Kaiser P, Won KA, Sangfelt O, Reed SI. Human F-box protein HCdc4 targets cyclin E for proteolysis and is mutated in a breast cancer cell line. Nature 2001; 413(6853): 316-322.
24. Koepp DM, Schaefer LK, Ye X, et al. Phosphorylation-dependent ubiquitination of cyclin E by the SCFFbw7 ubiquitin ligase. Science 2001; 294(5540): 173-177.
25. Moberg KH, Bell DW, Wahrer DC, Haber DA, Hariharan IK. Archipelago regulates cyclin E levels in Drosophila and is mutated in human cancer cell lines. Nature 2001; 413(6853): 311-316.
26. Carrano AC, Eytan E, Hershko A, Pagano M. SKP2 Is required for ubiquitin-mediated degradation of the CDK inhibitor P27. Nat Cell Biol 1999; 1(4): 193-199.
27. Tedesco D, Lukas J, Reed SI. The PRb-related protein P130 is regulated by phosphorylation-dependent proteolysis via the protein-ubiquitin ligase SCF(Skp2. Genes Dev 2002; 16(22): 2946-2957.
28. Gstaiger M, Jordan R, Lim M, et al. Skp2 is oncogenic and overexpressed in human cancers. Proc Natl Acad Sci USA 2001; 98(9): 5043-5048.
29. Signoretti S, Di Marcotullio L, Richardson A, et al. Oncogenic role of the ubiquitin ligase subunit Skp2 in human breast cancer. J Clin Invest 2002; 110(5): 633-641.
30. Hershko D, Bornstein G, Ben Izhak O, et al. Inverse relation between levels of P27(Kip1) and of its ubiquitin ligase subunit Skp2 in colorectal carcinomas. Cancer 2001; 91(9): 1745-1751.
31. Chiarle R, Fan Y, Piva R, et al. S-phase kinase-associated protein 2 expression in non-Hodgkin's lymphoma inversely correlates with P27 expression and defines cells in S phase. Am J Pathol 2002; 160(4): 1457-1466.
32. Masuda TA, Inoue H, Sonoda H, et al. Clinical and biological significance of S-phase kinase-associated protein 2 (Skp2) gene expression in gastric carcinoma: modulation of malignant phenotype by Skp2 overexpression, possibly via P27 proteolysis. Cancer Res 2002; 62(13): 3819-3825.
33. Yokoi S, Yasui K, Saito-Ohara F, et al. A novel target gene, SKP2, within the 5p13 amplicon that is frequently detected in small cell lung cancers. Am J Pathol 2002; 161(1): 207-216.
34. Schiffer D, Cavalla P, Fiano V, Ghimenti C, Piva R. Inverse relationship between P27/Kip.1 and the F-box protein Skp2 in human astrocytic gliomas by immunohistochemistry and Western blot. Neurosci Lett 2002; 328(2): 125-128.
35. Lim MS, Adamson A, Lin Z, et al. Expression of Skp2, a P27(Kip1) ubiquitin ligase, in malignant lymphoma: correlation with P27(Kip1) and proliferation index. Blood 2002; 100(8): 2950-2956.
36. Yang G, Ayala G, Marzo AD, et al. Elevated Skp2 protein expression in human prostate cancer: association with loss of the cyclin-dependent kinase inhibitor P27 and PTEN and with reduced recurrence-free survival. Clin Cancer Res 2002; 8(11): 3419-3426.
37. Mamillapalli R, Gavrilova N, Mihaylova VT, et al. PTEN regulates the ubiquitin-dependent degradation of the CDK inhibitor P27(KIP1) through the ubiquitin E3 ligase SCF(SKP2. Curr Biol 2001; 11(4): 263-267.
38. Coats S, Whyte P, Fero ML, et al. A new pathway for mitogen-dependent Cdk2 regulation uncovered in P27(Kip1)-deficient cells. Curr Biol 1999; 9(4): 163-173.
39. Lane DP, Lain S. Therapeutic exploitation of the P53 pathway. Trends Mol Med 2002; 8(4 Suppl): S38-S42.
40. Balint EE, Vousden KH. Activation and activities of the P53 tumour suppressor protein. Br J Cancer 2001; 85(12): 1813-1823.
41. Prasad G, Wang H, Agrawal S, Zhang R. Antisense anti-MDM2 oligonucleotides as a novel approach to the treatment of glioblastoma multiforme. Anticancer Res 2002; 22(1A): 107-116.
42. Bottger V, Bottger A, Howard SF, et al. Identification of novel Mdm2 binding peptides by phage display. Oncogene 1996; 13(10): 2141-2147.
43. Bottger A, Bottger V, Sparks A, Liu WL, Howard SF, Lane DP. Design of a synthetic Mdm2-binding mini protein that activates the P53 response in vivo. Curr Biol 1997; 7(11): 860-869.
44. Inoue S, Orimo A, Hosoi T, et al. Genomic binding-site cloning reveals an estrogen-responsive gene that encodes a RING finger protein. Proc Natl Acad Sci USA 1993; 90(23): 11117-11121.
45. Ikeda K, Orimo A, Higashi Y, Muramatsu M, Inoue S. Efp as a primary estrogen-responsive gene in human breast cancer. FEBS Lett 2000; 472(1): 9-13.
46. Thomson SD, Ali S, Pickles L, et al. Analysis of estrogen-responsive finger protein expression in benign and malignant human breast. Int J Cancer 2001; 91(2): 152-158.
47. Urano T, Saito T, Tsukui T, et al. Efp targets 14-3-3σ for proteolysis and promotes breast tumour growth. Nature 2002; 417(6891): 871-875.
48. Hermeking H, Lengauer C, Polyak K, et al. 14-3-3σ is a P53-regulated inhibitor of G2/M progression. Mol Cell 1997; 1(1): 3-11.
49. Chan TA, Hermeking H, Lengauer C, Kinzler KW, Vogelstein B. 14-3-3σ is required to prevent mitotic catastrophe after DNA damage. Nature 1999; 401(6753): 616-620.
50. Deshaies RJ. SCF and cullin/ring H2-based ubiquitin ligases. Annu Rev Cell Dev Biol 1999; 15: 435-467.
51. Wu K, Chen A, Pan ZQ. Conjugation of Nedd8 to CUL1 enhances the ability of the ROC1-CUL1 complex to promote ubiquitin polymerization. J Biol Chem 2000; 275(41): 32317-32324.
52. Tanaka K, Suzuki T, Chiba T. The ligation systems for ubiquitin and ubiquitin-like proteins. Mol Cell 1998; 8(5): 503-512.
53. Lyapina S, Cope G, Shevchenko A, et al. Promotion of NEDD-CUL1 conjugate cleavage by COP9 signalosome. Science 2001; 292(5520): 1382-1385.
54. Cope GA, Suh GS, Aravind L, et al. Role of predicted metalloprotease motif of Jab1/Csn5 in cleavage of Nedd8 from Cul1. Science 2002; 298(5593): 608-611.
55. Verma R, Aravind L, Oania R, et al. Role of Rpn11 metalloprotease in deubiquitination and degradation by the 26S proteasome. Science 2002; 298(5593): 611-615.